WTA introduces gene testing for all players on women’s tennis tour

The Women’s Tennis Association recently announced a new mandate for all players. Starting this week, every competitor must undergo one-off gene testing as part of an updated eligibility policy. This requirement exists specifically to preserve the integrity of women’s professional tennis and ensure consistent competitive conditions across the tour.

The policy change aligns with guidelines set by the International Olympic Committee. These rules reflect an executive order regarding sports eligibility ahead of the 2028 Los Angeles Olympics. By implementing these measures, the association brings its standards into agreement with the requirements necessary for Olympic participation.

Under the new protocols, the organization distinguishes between biological sex and gender identity. Testing focuses on identifying the presence of the SRY gene, which is a segment of DNA found on the Y chromosome. According to the policy, an individual is considered a biological male if they possess this gene, regardless of legal status or identity. The association maintains that these tests are meant to standardize entry criteria for professional events rather than question the dignity of any person.

While this approach follows actions already taken by governing bodies in other sports such as track and field, skiing, and boxing, it continues to face scrutiny. Various human rights experts and activist groups have expressed criticism regarding the implementation of mandatory genetic screening. The association moves forward with these requirements as it prepares for the upcoming Olympic cycle.